HomeESPR • NASDAQ
add
Esperion Therapeutics Inc
Previous close
$2.47
Day range
$2.38 - $2.59
Year range
$0.69 - $4.18
Market cap
626.62M USD
Avg Volume
4.39M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 168.45M | 143.73% |
Operating expense | 41.43M | 12.21% |
Net income | 61.83M | 390.04% |
Net profit margin | 36.71 | 219.00% |
Earnings per share | 0.22 | 319.12% |
EBITDA | 85.26M | 2,040.79% |
Effective tax rate | 2.89% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 167.85M | 15.95% |
Total assets | 465.89M | 35.50% |
Total liabilities | 767.85M | 4.82% |
Total equity | -301.96M | — |
Shares outstanding | 256.81M | — |
Price to book | -2.01 | — |
Return on assets | 51.35% | — |
Return on capital | 107.71% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 61.83M | 390.04% |
Cash from operations | 45.24M | 229.44% |
Cash from investing | — | — |
Cash from financing | 30.16M | -13.81% |
Net change in cash | 75.40M | 171,275.00% |
Free cash flow | 958.12K | 102.05% |
About
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Website
Employees
294
